
Biontech, a spinout of Johannes Gutenberg University Mainz, has received $91.5m in funding as part of the extension of a deal to develop a cancer immunotherapy candidate with Sanofi.
Oxford spinout Argonaut Therapeutics has received $2.6m from JW Pharmaceuticals in return for a 25% stake.
Nova University Lisbon has established chemicals producer Des Solutio with the support of Frontier IP, making it the second spinout launched in Portugal by the commercialisation firm.
Johns Hopkins oncology diagnostics spinout PGDx had previously raised approximately $99m.
Medical imaging company iThera spun out of Helmholtz Zentrum München in 2010 and has now been backed by lighting products maker Osram.
The cancer therapy developer has secured $120m in a convertible note offering featuring the University of California office of the chief investment officer.
Vesalius has provided $4.7m to Forendo Pharma, whose existing shareholders also include Karolinska Development, Novartis, Novo and Merck Group.
Biontech, an immunotherapy spinout of Johannes Gutenberg University Mainz, has received an undisclosed amount of equity funding as part of a collaboration deal that could reach $425m.
Endocrine disease therapy developer Millendo, spun out of University of Michigan, will merge with publicly-listed OvaScience, raising a further $30m in the process.